Paul Kwon Selected Research

efalizumab (Raptiva)

6/2007	Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
4/2006	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
4/2006	Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
1/2006	A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
1/2006	An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
12/2005	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
11/2005	Immune thrombocytopenia associated with efalizumab therapy for psoriasis.
4/2005	Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.
3/2005	Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Kwon Research Topics

Disease

9	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2007 - 03/2005
8	Neoplasms (Cancer) 01/2021 - 01/2004
4	Pruritus (Itching) 12/2020 - 05/2019
2	Prurigo 08/2019 - 05/2019
1	Epidermolysis Bullosa 06/2020
1	Seborrheic Dermatitis 06/2020
1	Nasopharyngitis 05/2019
1	Diarrhea 05/2019
1	Fatigue 05/2019
1	Benign Migratory Glossitis (Geographic Tongue) 10/2017
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 11/2010
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2006
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2006
1	Skin Neoplasms (Skin Cancer) 01/2006
1	Melanoma (Melanoma, Malignant) 01/2006
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/2005

Drug/Important Bio-Agent (IBA)

9	efalizumab (Raptiva)FDA Link 06/2007 - 03/2005
4	serlopitantIBA 12/2020 - 05/2019
3	Histone Deacetylases (Histone Deacetylase)IBA 07/2011 - 01/2004
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2018
2	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 06/2020 - 05/2019
2	Neurokinin-1 Receptor AntagonistsIBA 06/2020 - 05/2019
2	Histone Deacetylase InhibitorsIBA 07/2011 - 01/2004
2	Immunoglobulin G (IgG)IBA 01/2006 - 01/2006
2	Histones (Histone)IBA 01/2004 - 01/2004
2	LAQ824IBA 01/2004 - 01/2004
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	Substance PIBA 06/2020
1	regorafenibIBA 01/2018
1	Imatinib Mesylate (Gleevec)FDA Link 01/2018
1	Sunitinib (Sutent)FDA Link 01/2018
1	HLA-DP Antigens (HLA-DP)IBA 10/2017
1	HLA-DR Antigens (HLA-DR)IBA 10/2017
1	AntigensIBA 10/2017
1	HLA Antigens (Human Leukocyte Antigens)IBA 10/2017
1	CarcinogensIBA 01/2015
1	PanobinostatIBA 11/2010
1	Monoclonal AntibodiesIBA 01/2006
1	Immunoglobulins (Immunoglobulin)IBA 01/2006
1	Annexin A5IBA 01/2004
1	Pharmaceutical PreparationsIBA 01/2004

Therapy/Procedure

6	Therapeutics 08/2019 - 11/2005
1	Retreatment 04/2006